Clinical Trial Update: Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial results for ruxolitinib (INCB018424) in patients with myelofibrosis, including those with post-polycythemia vera/essential thrombocyt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Myelofibrosis, Polycythemia Vera | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-08-02